ACHV
Income statement / Annual
Last year (2024), Achieve Life Sciences, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Achieve Life Sciences, Inc.'s net income was -$39.83 M.
See Achieve Life Sciences, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$5.06 M |
$18.16 M |
| Cost of Revenue |
$0.00
|
$228.00 K
|
$236.00 K
|
$250.00 K
|
$255.00 K
|
$254.00 K
|
$282.00 K
|
$282.00 K
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
-$228.00 K
|
-$236.00 K
|
-$250.00 K
|
-$255.00 K
|
-$254.00 K
|
-$282.00 K
|
-$282.00 K
|
$5.06 M
|
$18.16 M
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
| Research and Development Expenses |
$22.82 M
|
$15.81 M
|
$30.08 M
|
$23.97 M
|
$6.88 M
|
$9.67 M
|
$5.87 M
|
$3.10 M
|
$14.79 M
|
$25.11 M
|
| General & Administrative Expenses |
$16.25 M
|
$11.44 M
|
$10.72 M
|
$9.13 M
|
$7.87 M
|
$6.85 M
|
$6.95 M
|
$3.53 M
|
$8.93 M
|
$11.81 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.25 M
|
$11.44 M
|
$10.72 M
|
$9.13 M
|
$7.87 M
|
$6.85 M
|
$6.95 M
|
$3.53 M
|
$8.93 M
|
$11.81 M
|
| Other Expenses |
$0.00
|
$0.00
|
-$1.55 M
|
-$58.00 K
|
-$49.00 K
|
$133.00 K
|
$126.00 K
|
$165.00 K
|
$1.06 M
|
$1.95 M
|
| Operating Expenses |
$39.07 M
|
$27.02 M
|
$40.80 M
|
$33.09 M
|
$14.75 M
|
$16.53 M
|
$12.81 M
|
$6.63 M
|
$23.72 M
|
$36.91 M
|
| Cost And Expenses |
$0.00
|
$27.25 M
|
$40.80 M
|
$33.09 M
|
$14.75 M
|
$16.53 M
|
$12.81 M
|
$6.63 M
|
$23.72 M
|
$36.91 M
|
| Interest Income |
$2.36 M
|
$825.00 K
|
$199.00 K
|
$17.00 K
|
$69.00 K
|
$170.00 K
|
$171.00 K
|
$21.00 K
|
$203.00 K
|
$119.00 K
|
| Interest Expense |
$2.18 M
|
$2.85 M
|
$1.79 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$229.00 K
|
$228.00 K
|
$236.00 K
|
$250.00 K
|
$255.00 K
|
$254.00 K
|
$282.00 K
|
$282.00 K
|
$188.00 K
|
$244.00 K
|
| EBITDA |
-$37.42 M |
-$26.73 M |
-$40.33 M |
-$32.90 M |
-$14.48 M |
-$16.14 M |
-$12.41 M |
-$13.35 M |
-$19.94 M |
-$16.56 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-3.94
|
-0.91
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-4.19
|
-1.03
|
| Total Other Income/Expenses Net |
-$758.00 K
|
-$2.57 M
|
-$1.55 M
|
-$58.00 K
|
$20.00 K
|
$133.00 K
|
$126.00 K
|
-$7.00 M
|
-$1.47 M
|
$1.95 M
|
| Income Before Tax |
-$39.83 M
|
-$29.82 M
|
-$42.35 M
|
-$33.15 M
|
-$14.73 M
|
-$16.40 M
|
-$12.69 M
|
-$13.63 M
|
-$20.13 M
|
-$16.80 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-3.98
|
-0.93
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$475.00 K
|
-$250.00 K
|
-$69.00 K
|
-$254.00 K
|
-$126.00 K
|
-$3.05 M
|
-$1.06 M
|
-$1.95 M
|
| Net Income |
-$39.83 M
|
-$29.82 M
|
-$41.88 M
|
-$32.90 M
|
-$14.66 M
|
-$16.14 M
|
-$12.69 M
|
-$10.58 M
|
-$20.13 M
|
-$16.80 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-3.98
|
-0.93
|
| EPS |
-1.24 |
-1.5 |
-3.95 |
-4.05 |
-5.39 |
-39.15 |
-72.29 |
-441.47 |
-1478.66 |
-1413.63 |
| EPS Diluted |
-1.24 |
-1.5 |
-3.95 |
-4.05 |
-5.39 |
-39.15 |
-72.29 |
-441.47 |
-1474.98 |
-1413.63 |
| Weighted Average Shares Out |
$32.07 M
|
$19.83 M
|
$10.59 M
|
$8.12 M
|
$2.72 M
|
$412.32 K
|
$175.51 K
|
$23.97 K
|
$13.61 K
|
$11.89 K
|
| Weighted Average Shares Out Diluted |
$32.07 M
|
$19.83 M
|
$10.59 M
|
$8.12 M
|
$2.72 M
|
$412.32 K
|
$175.51 K
|
$23.97 K
|
$13.65 K
|
$11.89 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
